Werewolf Therapeutics, Inc. (HOWL) Dividend History

Company News

• Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

  Werewolf Therapeutics provided updates on its clinical trials, including progress with WTX-124 and WTX-330, and announced the development of its proprietary INDUCER T cell engager molecules. The company also reported its financial results for the first quarter of 2025, with a cash runway into the fourth quarter of 2026.

  GlobeNewswire Inc.
• Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

  Werewolf Therapeutics, a biopharmaceutical company, announced the appointment of Steven Bloom as Chief Business Officer. Bloom brings over 35 years of experience in the life sciences industry and will help Werewolf navigate important milestones, including data from a clinical trial and pipeline development.

  GlobeNewswire Inc.
• Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

  Werewolf Therapeutics, a biopharmaceutical company, announced that it will present two posters at the upcoming SITC 39th Annual Meeting. The posters will focus on the company's INDUKINE molecules and their potential in treating solid tumors.

  GlobeNewswire Inc.
• Where Werewolf Therapeutics Stands With Analysts

  Ratings for Werewolf Therapeutics (NASDAQ:HOWL) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Werewolf Therapeutics, presenting an average target of $13.71, a high estimate of $15.00, and a low estimate of $12.00. Highlighting a 2.07% decrease, the current average has fallen from the previous average price target of $14.00. Diving into Analyst Ratings: An In-Depth Exploration In examining recent analyst actions, we gain insights into how financial experts perceive Werewolf Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andres Maldonado HC Wainwright & Co. Maintains Buy $15.00 $15.00 Reni Benjamin JMP Securities Maintains Market Outperform $12.00 $12.00 Andres Maldonado HC Wainwright & Co. Maintains Buy $15.00 $15.00 Andres Maldonado HC Wainwright & Co. Maintains Buy $15.00 $15.00 Reni Benjamin JMP Securities Maintains Market Outperform $12.00 $12.00 Andres Maldonado HC Wainwright & Co. Maintains Buy $15.00 $15.00 Reni Benjamin JMP Securities Announces Market Outperform $12.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction ...Full story available on Benzinga.com

  Benzinga
• Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

  - Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 -

  GlobeNewswire Inc.